NASDAQ
REGN
Last Price
US $803.48
KEY FIGURES
MKT CAP
$82.8B
EPS
TTM
$41.86
PEG
TTM
60.15x
P/E
TTM
19.19x
P/S
TTM
5.35x
YIELD
0.45%
GROWTH
Revenue Y/Y
Profit margin
Current Ratio
Capital Returns
13.81%
Return on equity
ROIC: 9.19%
Valuation History
18.7X
Price to Earnings
EV/EBITDA: 14.3X
Cash flow
Profit margin
11.04%
(FY vs FY)
EBITDA Y/Y
7.23%
(FY vs FY)
Cash flow Y/Y
15.29%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $803.48
-12.75%
Default assumptions
EBITDA Multiple
Fair Value
Market $803.48
-50.72%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Regeneron Pharmaceuticals, Inc. cash flow to debt ratio of 184.00% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial stability - Healthy cash flow growth.
Regeneron Pharmaceuticals, Inc.'s free cash flow has increased 11.35% from $3.66G last year to $4.08G, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Regeneron Pharmaceuticals, Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Regeneron Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.09 last year to 0.06 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Regeneron Pharmaceuticals, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Regeneron Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Regeneron Pharmaceuticals, Inc.'s profit margin has decreased (-10.32%) in the last year from 31.07% to 27.86%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Regeneron Pharmaceuticals, Inc.'s short-term assets of $18.02G exceed its short-term liabilities of $4.37G
Increasing performance - ROA.
Regeneron Pharmaceuticals, Inc.'s return on assets of 10.37% is higher than the 5.00% threshold, indicating efficient asset utilization
Decreasing performance - Absolute return on equity.
Regeneron Pharmaceuticals, Inc.'s return on equity of 13.81%, is lower than 15.00%, indicating bad performance
Increasing performance - Earnings quality.
Regeneron Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Regeneron Pharmaceuticals, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Regeneron Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Regeneron Pharmaceuticals, Inc. has a free cash flow yield of 4.93%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Regeneron Pharmaceuticals, Inc.'s yearly earnings has increased 2.09% since last year from $4.41G to $4.50G, signaling increasing performance
Increasing performance - Healthy revenue growth.
Regeneron Pharmaceuticals, Inc.'s yearly revenue has increased 0.99% since last year from $14.20G to $14.34G, signaling increasing performance
Increasing performance - ROIC.
ROIC 9.19% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
Increasing performance - 3-year revenue CAGR.
Regeneron Pharmaceuticals, Inc.'s 3-year revenue CAGR of 5.62% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Regeneron Pharmaceuticals, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Regeneron Pharmaceuticals, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Regeneron Pharmaceuticals, Inc. is overvalued relative to its fair value price of 701.06 based on Discounted Cash Flow model
Undervalued - Earnings yield.
Regeneron Pharmaceuticals, Inc. has an earnings yield of 5.21%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Regeneron Pharmaceuticals, Inc. is overvalued relative to its fair value price of 395.95 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Regeneron Pharmaceuticals, Inc. has an EV/EBITDA ratio of 14.16x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Regeneron Pharmaceuticals, Inc. has a PEG-ratio over 1 which is considered overvalued
Undervalued - P/B ratio.
Regeneron Pharmaceuticals, Inc. has a price-to-book ratio of 2.62x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Regeneron Pharmaceuticals, Inc. has a price-to-sales ratio of 5.35x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue